Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)

Volume: 26, Issue: 12, Pages: 1111
Published: Dec 1, 2020
Abstract
Background null Patients with chronic kidney disease (CKD) are at high risk of adverse renal and cardiovascular (CV) outcomes, particularly heart failure. We investigated the effects of dapagliflozin inpatients with CKD, with and without type 2 diabetes (T2D). DAPA-CKD is the first trial to test the effects of a SGLT2 inhibitor on renal and CV outcomes in CKD patients without T2D and included patients with a lower eGFR than in prior trials. null...
Paper Details
Title
Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)
Published Date
Dec 1, 2020
Volume
26
Issue
12
Pages
1111
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.